

Burlington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	21	25.7	81.8	(50.6-125.1)	Male	19	16.5	115.1	(69.3-179.8)
Female	6	9.1	65.7	(24.0-142.9)	Female	15	13.1	114.7	(64.1-189.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	5.0	100.1	(32.2-233.5)	Male	5	4.1	121.4	(39.1-283.4)
Female	4	4.0	nc	(nc-nc)	Female	3	2.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.9	nc	(nc-nc)	Male	13	13.9	93.5	(49.8-160.0)
Female	100	95.0	105.2	(85.6-128.0)	Female	11	11.9	92.5	(46.1-165.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	5	4.1	122.0	(39.3-284.7)	Male	6	10.5	57.1	(20.9-124.3)
<u>Colon / Rectum</u>					Female	7	4.7	149.9	(60.0-308.8)
Male	24	36.5	65.8	(42.1-97.9)	<u>Ovary</u>				
Female	35	31.6	110.6	(77.0-153.9)	Female	4	9.8	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	7	7.1	99.0	(39.6-203.9)	Male	8	8.0	100.4	(43.2-197.8)
Female	3	1.7	nc	(nc-nc)	Female	9	7.7	117.5	(53.6-223.0)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	2.1	nc	(nc-nc)	Male	110	107.6	102.3	(84.1-123.3)
Female	4	1.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	6	5.8	103.5	(37.8-225.2)
Male	8	12.8	62.4	(26.9-123.0)	Female	2	3.3	nc	(nc-nc)
Female	6	7.6	78.9	(28.8-171.8)	<u>Testis</u>				
<u>Larynx</u>					Male	4	3.7	nc	(nc-nc)
Male	2	4.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	1.2	nc	(nc-nc)	Male	4	4.3	nc	(nc-nc)
<u>Leukemia</u>					Female	15	13.1	114.9	(64.3-189.5)
Male	14	8.4	166.1	(90.7-278.7)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	6	6.2	96.1	(35.1-209.3)	Female	24	22.2	108.2	(69.3-161.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	6	6.3	95.6	(34.9-208.0)	Male	341	358.3	95.2	(85.3-105.8)
Female	1	2.0	nc	(nc-nc)	Female	346	322.9	107.1	(96.1-119.0)
<u>Lung and Bronchus</u>									
Male	51	49.7	102.6	(76.4-134.9)					
Female	50	46.2	108.3	(80.3-142.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;